Biased Ligands. Better Drugs.

TRV027 - AT1R Biased Ligand for Acute Heart Failure

Target Indication Lead
Optimization
Preclinical
Development
Phase
1
Phase
2
Phase
3
OwnershipCollaborator
TRV027 Angiotensin II type 1 receptor Acute Heart Failure intravenous Allergan
Oliceridine (TRV130) Mu-receptor Moderate to
Severe Pain
intravenous Trevena Logo
TRV734 Mu-receptor Moderate to
Severe Pain
oral Trevena Logo
TRV250 Delta-receptor Treatment Refractory Migraine oral Trevena Logo

TRV027 is an intravenous drug for the treatment of acute heart failure (AHF) in combination with standard diuretic therapy, and is currently being investigated in a Phase 2 clinical trial. TRV027 is a β-arrestin biased ligand of the angiotensin II type 1 receptor (AT1R). Allergan plc (NYSE:AGN) has an exclusive option to license TRV027.

View TRV027 Publications

Copyright © Trevena, Inc.